CNV
Clinical trials for CNV explained in plain language.
Never miss a new study
Get alerted when new CNV trials appear
Sign up with your email to follow new studies for CNV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…
Matched conditions: CNV
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Gene therapy could end frequent eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to help the eye produce its own medicine to stop leaky blood vessels, potentially replacing the need for repeated eye injecti…
Matched conditions: CNV
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC